{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:41:35Z","timestamp":1788414095194,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) each play a central role in the pathogenesis of chronic kidney disease-mineral and bone disorder (CKD-MBD). Both hormones increase as kidney function declines, presumably as a response to maintain normal phosphate balance, but when patients reach kidney failure, PTH and FGF23 fail to exert their phosphaturic effects, leading to hyperphosphatemia and further elevations in PTH and FGF23. In patients with kidney failure, the major target organ for PTH is the bone, but elevated PTH is also associated with mortality\u00a0presumably through skeletal and\u00a0nonskeletal mechanisms. Indeed, accumulated evidence suggests improved survival with PTH-lowering therapies, and a more recent study comparing parathyroidectomy and calcimimetic treatment further suggests a notion of \u201cthe lower, the better\u201d for PTH control. Emerging data suggest that the link between SHPT and mortality could in part be explained by the action of PTH to induce adipose tissue browning and wasting. In the absence of a functioning kidney, the classical target organ for FGF23 is the parathyroid gland, but FGF23 loses its hormonal effect to suppress PTH secretion owing to the depressed expression of parathyroid Klotho. In this setting, experimental data suggest that FGF23 exerts adverse nontarget effects, but it remains to be confirmed whether FGF23 directly contributes to multiple organ injury in patients with kidney failure\u00a0and whether targeting FGF23 can improve patient outcomes. Further efforts should be made to determine whether intensive control of SHPT improves clinical outcomes and whether nephrologists should aim at controlling FGF23 levels just as with PTH levels.<\/jats:p>","DOI":"10.1007\/s10157-023-02336-y","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:03:22Z","timestamp":1680005002000},"page":"395-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-4507","authenticated-orcid":false,"given":"Hirotaka","family":"Komaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"2336_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10157-021-02049-0","volume":"25","author":"K Nagai","year":"2021","unstructured":"Nagai K, Asahi K, Iseki K, Yamagata K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2021;25:885\u201392.","journal-title":"Clin Exp Nephrol"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2016.09.015","volume":"91","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227\u201334.","journal-title":"Kidney Int"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2215\/CJN.04940512","volume":"7","author":"BM Robinson","year":"2012","unstructured":"Robinson BM, Bieber B, Pisoni RL, Port FK. Dialysis outcomes and practice patterns study (DOPPS): its strengths, limitations, and Role in informing practices and policies. Clin J Am Soc Nephrol. 2012;7:1897\u2013905.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2336_CR4","first-page":"1","volume":"2017","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;2017(7):1\u201359.","journal-title":"Kidney Int Suppl"},{"issue":"Suppl 3","key":"2336_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ndt\/11.supp3.130","volume":"11","author":"E Slatopolsky","year":"1996","unstructured":"Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996;11(Suppl 3):130\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"2336_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","volume":"44","author":"T Shigematsu","year":"2004","unstructured":"Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250\u20136.","journal-title":"Am J Kidney Dis"},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/ki.2010.313","volume":"78","author":"H Hasegawa","year":"2010","unstructured":"Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78:975\u201380.","journal-title":"Kidney Int"},{"key":"2336_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.2009.466","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010;77:292\u20138.","journal-title":"Kidney Int"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.xkme.2019.09.007","volume":"2","author":"C Kawabata","year":"2019","unstructured":"Kawabata C, Komaba H, Ishida H, Nakagawa Y, Hamano N, Koizumi M, et al. Changes in fibroblast growth factor 23 and soluble klotho levels after hemodialysis initiation. Kidney Medicine. 2019;2:59\u201367.","journal-title":"Kidney Medicine"},{"key":"2336_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70:1358\u201366.","journal-title":"Kidney Int"},{"key":"2336_CR12","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52:519\u201330.","journal-title":"Am J Kidney Dis"},{"key":"2336_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1744-9987.12030","volume":"17","author":"M Taniguchi","year":"2013","unstructured":"Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17:221\u20138.","journal-title":"Ther Apher Dial"},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","unstructured":"EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482\u201394.","journal-title":"N Engl J Med"},{"key":"2336_CR16","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/j.1523-1755.2004.00972.x","volume":"66","author":"B Kestenbaum","year":"2004","unstructured":"Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66:2010\u20136.","journal-title":"Kidney Int"},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2015.72","volume":"88","author":"H Komaba","year":"2015","unstructured":"Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;88:350\u20139.","journal-title":"Kidney Int"},{"key":"2336_CR18","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/ndt\/gfv334","volume":"30","author":"KM Ivarsson","year":"2015","unstructured":"Ivarsson KM, Akaberi S, Isaksson E, Reihn\u00e9r E, Rylance R, Pr\u00fctz KG, et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transplant. 2015;30:2027\u201333.","journal-title":"Nephrol Dial Transplant"},{"key":"2336_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MNH.0000000000000326","volume":"26","author":"H Komaba","year":"2017","unstructured":"Komaba H, Nakamura M, Fukagawa M. Resurgence of parathyroidectomy. Curr Opin Nephrol Hypertens. 2017;26:243\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2336_CR20","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1210\/clinem\/dgac142","volume":"107","author":"H Komaba","year":"2022","unstructured":"Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, et al. Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metabolism. 2022;107:2016\u201325.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2336_CR21","doi-asserted-by":"publisher","first-page":"e3532","DOI":"10.1210\/clinem\/dgac211","volume":"107","author":"P Evenepoel","year":"2022","unstructured":"Evenepoel P, J\u00f8rgensen HS. Parathyroidectomy versus calcimimetic: the lower the PTH the better? J Clin Endocrinol Metab. 2022;107:e3532\u20133.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2336_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","volume":"12","author":"Guideline Working Group","year":"2008","unstructured":"Guideline Working Group. Japanese society for dialysis therapy clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008;12(6):514\u201325.","journal-title":"Ther Apher Dial"},{"key":"2336_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12882-018-1056-5","volume":"19","author":"S Yamamoto","year":"2018","unstructured":"Yamamoto S, Karaboyas A, Komaba H, Taniguchi M, Nomura T, Bieber BA, et al. Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the dialysis outcomes and practice patterns study (DOPPS). BMC Nephrol. 2018;19:253.","journal-title":"BMC Nephrol"},{"key":"2336_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014;85:166\u201373.","journal-title":"Kidney Int"},{"key":"2336_CR25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/sj.ki.5000297","volume":"69","author":"K Lomashvili","year":"2006","unstructured":"Lomashvili K, Garg P, O\u2019Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int. 2006;69:1464\u201370.","journal-title":"Kidney Int"},{"key":"2336_CR26","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/01.ASN.0000141961.49723.BC","volume":"15","author":"L Cuppari","year":"2004","unstructured":"Cuppari L, de Carvalho AB, Avesani CM, Kamimura MA, Dos Santos Lob\u00e3o RR, Draibe SA. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol. 2004;15:2933\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","volume":"23","author":"S Kir","year":"2016","unstructured":"Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, et al. PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 2016;23:315\u201323.","journal-title":"Cell Metab"},{"key":"2336_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513:100\u20134.","journal-title":"Nature"},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/jcsm.12722","volume":"12","author":"H Komaba","year":"2021","unstructured":"Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, et al. Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. J Cachexia Sarcopenia Muscle. 2021;12:855\u201365.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"Suppl 1","key":"2336_CR30","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/01.ASN.0000093369.09194.12","volume":"15","author":"D Brancaccio","year":"2004","unstructured":"Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol. 2004;15(Suppl 1):S21\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/418695","volume":"2010","author":"AS Geara","year":"2010","unstructured":"Geara AS, Castellanos MR, Bassil C, Schuller-Levis G, Park E, Smith M, et al. Effects of parathyroid hormone on immune function. Clin Dev Immunol. 2010;2010: 418695.","journal-title":"Clin Dev Immunol"},{"key":"2336_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10157-016-1369-2","volume":"21","author":"H Komaba","year":"2017","unstructured":"Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol. 2017;21:37\u201345.","journal-title":"Clin Exp Nephrol"},{"key":"2336_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/ndt\/gfr384","volume":"27","author":"M Koizumi","year":"2012","unstructured":"Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transpl. 2012;27:784\u201390.","journal-title":"Nephrol Dial Transpl"},{"key":"2336_CR34","doi-asserted-by":"publisher","first-page":"E652","DOI":"10.1210\/jc.2013-4050","volume":"99","author":"H Takahashi","year":"2014","unstructured":"Takahashi H, Komaba H, Takahashi Y, Sawada K, Tatsumi R, Kanai G, et al. Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metabolism. 2014;99:E652\u20138.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2336_CR35","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882\u20139.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2336_CR36","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003\u20138.","journal-title":"J Clin Invest"},{"key":"2336_CR37","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/ki.2009.414","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232\u20138.","journal-title":"Kidney Int"},{"key":"2336_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ki.2009.464","volume":"77","author":"H Galitzer","year":"2010","unstructured":"Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77:211\u20138.","journal-title":"Kidney Int"},{"key":"2336_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1681\/ASN.2009040427","volume":"21","author":"R Canalejo","year":"2010","unstructured":"Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21:1125\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR40","doi-asserted-by":"publisher","first-page":"E3749","DOI":"10.1073\/pnas.1717754115","volume":"115","author":"Y Fan","year":"2018","unstructured":"Fan Y, Liu W, Bi R, Densmore MJ, Sato T, Mannstadt M, et al. Interrelated role of Klotho and calcium-sensing receptor in parathyroid hormone synthesis and parathyroid hyperplasia. Proc Natl Acad Sci U S A. 2018;115:E3749\u201358.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2336_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.bone.2011.06.025","volume":"49","author":"Y Rhee","year":"2011","unstructured":"Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011;49:636\u201343.","journal-title":"Bone"},{"key":"2336_CR42","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1096\/fj.201601036R","volume":"31","author":"J Kaludjerovic","year":"2017","unstructured":"Kaludjerovic J, Komaba H, Sato T, Erben RG, Baron R, Olauson H, et al. Klotho expression in long bones regulates FGF23 production during renal failure. FASEB J. 2017;31:2050\u201364.","journal-title":"FASEB J"},{"key":"2336_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.kint.2017.02.014","volume":"92","author":"H Komaba","year":"2017","unstructured":"Komaba H, Kaludjerovic J, Hu DZ, Nagano K, Amano K, Ide N, et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int. 2017;92:599\u2013611.","journal-title":"Kidney Int"},{"key":"2336_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/MNH.0000000000000423","volume":"27","author":"H Komaba","year":"2018","unstructured":"Komaba H, Lanske B. Role of klotho in bone and implication for CKD. Curr Opin Nephrol Hy. 2018;27:298\u2013304.","journal-title":"Curr Opin Nephrol Hy"},{"key":"2336_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/sj.ki.5002622","volume":"73","author":"P Urena Torres","year":"2008","unstructured":"Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Pri\u00e9 D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008;73:102\u20137.","journal-title":"Kidney Int"},{"key":"2336_CR46","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrneph.2012.116","volume":"8","author":"H Komaba","year":"2012","unstructured":"Komaba H, Fukagawa M. The role of FGF23 in CKD-with or without Klotho. Nat Rev Nephrol. 2012;8:484\u201390.","journal-title":"Nat Rev Nephrol"},{"key":"2336_CR47","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393\u2013408.","journal-title":"J Clin Invest"},{"key":"2336_CR48","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabmer","year":"2015","unstructured":"Grabmer A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22:1020\u201332.","journal-title":"Cell Metab"},{"key":"2336_CR49","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432\u20139.","journal-title":"JAMA"},{"key":"2336_CR50","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584\u201392.","journal-title":"N Engl J Med"},{"key":"2336_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1681\/ASN.2014101009","volume":"27","author":"M Chonchol","year":"2016","unstructured":"Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27:227\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR52","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ekir.2020.08.013","volume":"5","author":"H Komaba","year":"2020","unstructured":"Komaba H, Fuller DS, Taniguchi M, Yamamoto S, Nomura T, Zhao J, et al. Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the japan dialysis outcomes and practice patterns study. Kidney Int Rep. 2020;5:1956\u201364.","journal-title":"Kidney Int Rep"},{"key":"2336_CR53","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1681\/ASN.2010080894","volume":"22","author":"M Wolf","year":"2011","unstructured":"Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011;22:956\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"2336_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.kint.2018.02.017","volume":"94","author":"EM Pastor-Arroyo","year":"2018","unstructured":"Pastor-Arroyo EM, Gehring N, Krudewig C, Costantino S, Bettoni C, Kn\u00f6pfel T, et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int. 2018;94:49\u201359.","journal-title":"Kidney Int"},{"key":"2336_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/07435800.2016.1242604","volume":"42","author":"Y Takashi","year":"2017","unstructured":"Takashi Y, Kinoshita Y, Hori M, Ito N, Taguchi M, Fukumoto S. Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy. Endocr Res. 2017;42:132\u20137.","journal-title":"Endocr Res"},{"key":"2336_CR56","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/jbmr.2527","volume":"30","author":"O Andrukhova","year":"2015","unstructured":"Andrukhova O, Slavic S, Odorfer KI, Erben RG. Experimental myocardial infarction upregulates circulating fibroblast growth factor 23. J Bone Miner Res. 2015;30:1831\u20139.","journal-title":"J Bone Miner Res"},{"key":"2336_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.kint.2018.02.018","volume":"94","author":"I Matsui","year":"2018","unstructured":"Matsui I, Oka T, Kusunoki Y, Mori D, Hashimoto N, Matsumoto A, et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23. Kidney Int. 2018;94:60\u201371.","journal-title":"Kidney Int"},{"key":"2336_CR58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/2048872613494025","volume":"2","author":"J P\u00f6ss","year":"2013","unstructured":"P\u00f6ss J, Mahfoud F, Seiler S, Heine GH, Fliser D, B\u00f6hm M, et al. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2013;2:211\u20138.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2336_CR59","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.kint.2021.04.045","volume":"100","author":"H Komaba","year":"2021","unstructured":"Komaba H, Fukagawa M. Jury still out on whether FGF23 is a direct contributor, a useful biomarker, or neither. Kidney Int. 2021;100:989\u201393.","journal-title":"Kidney Int"},{"key":"2336_CR60","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985\u201396.","journal-title":"Kidney Int"},{"key":"2336_CR61","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1172\/JCI83470","volume":"126","author":"J Rossaint","year":"2016","unstructured":"Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenst\u00e4dt HJ, Meersch M, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126:962\u201374.","journal-title":"J Clin Invest"},{"key":"2336_CR62","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","volume":"289","author":"LM Coe","year":"2014","unstructured":"Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289:9795\u2013810.","journal-title":"J Biol Chem"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02336-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02336-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02336-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T12:03:01Z","timestamp":1681473781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02336-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02336-y","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HK has received grant support from Kyowa Kirin and honoraria from Chugai Pharmaceutical, Kissei Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Sanwa Kagaku Kenkyusho.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}